A recent tariff exemption agreement has ignited a rally in the U.S. stock market’s healthcare sector. Following Pfizer’s settlement with the U.S. government, market sentiment suggests a potentially more lenient environment for biopharma companies. However, beyond this short-term catalyst, true value may lie with companies like CRISPR Therapeutics (NASDAQ: CRSP) and BioNTech, which possess disruptive technologies poised to fuel the next healthcare revolution.
The healthcare sector experienced broad gains after Pfizer announced its agreement with the U.S. government on September 30. The deal grants Pfizer tariff exemptions in exchange for price reductions on certain drugs and increased domestic manufacturing investment. This not only boosted Pfizer’s stock but also lifted peers, including biotech firms, on expectations of similar future agreements.
Within this context, gene-editing specialist CRISPR Therapeutics and COVID-19 vaccine developer BioNTech have captured significant attention. Analysts note substantial potential upside for both stocks, though the core investment thesis is less tied to recent events and more rooted in their robust R&D pipelines and foundational technology platforms.
CRISPR Therapeutics currently has only one approved gene therapy, Casgevy, for two rare blood disorders. Priced at $2.2 million in the U.S. and targeting a patient pool of approximately 60,000, Casgevy’s current financial contribution is limited. However, analysts project it could eventually achieve blockbuster status.
The greater focus lies in CRISPR’s follow-up pipeline. Its lead drug candidates, CTX310 and CTX320, are in vivo gene-editing therapies. Unlike the ex vivo approach used for Casgevy, in vivo therapies avoid complex and time-consuming cell collection, offering greater clinical convenience.
Both candidates are expected to report clinical progress within the next year. Positive updates could serve as significant catalysts for the stock. While clinical trial and regulatory risks persist, CRISPR Therapeutics’ advanced gene-editing platform underscores its considerable long-term potential.
BioNTech, known globally for co-developing the COVID-19 vaccine Comirnaty with Pfizer, faces volatile and unpredictable revenue from its coronavirus products (Q2 revenue was €260.8 million). Its future is now firmly tied to its extensive oncology pipeline.
BioNTech’s cancer portfolio is particularly noteworthy. Its core candidate, BNT327, is viewed as a potential challenger to Merck’s blockbuster therapy Keytruda, which boasts annual sales exceeding $20 billion. Should BNT327 demonstrate superior efficacy or broader applicability, its market opportunity would be vast.
BNT327 is currently in clinical trials for various cancers, including lung, breast, and liver cancer. In a Phase 1b/2 trial for breast cancer, BNT327 showed overall survival data that appeared favorable compared to historical Keytruda data. While cross-trial comparisons have limitations, the results have bolstered market confidence. For investors, BioNTech is striving to prove it’s not a one-hit wonder. Continued progress in its oncology pipeline could trigger a significant re-rating of the company’s value.
Short-term policy tailwinds are providing a lift to the healthcare sector, but the investment narratives for CRISPR Therapeutics and BioNTech are rooted in the next revolutions of gene editing and cancer immunotherapy. For long-term value-oriented investors, these companies, with their cutting-edge platforms and promising pipelines, warrant close attention.
